Product Information
LEVONOR-ETH ESTRAD TRIPHASIC is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.3236 per EA under NDC 68180085773. Its NADAC has been published 300 times since Jan 6, 2021.
FDA first approved this application on Nov 19, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180085773
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA200248FDA Approved
11/19/2015
TE Code
AB
On Market Since
8/30/2020
Price Statistics
The NADAC for LEVONOR-ETH ESTRAD TRIPHASIC has been published 300 times since Jan 6, 2021, and over the history we have for it it has declined 31.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3236 per EA |
|---|---|
| All-time high | $0.5249 (Apr 14, 2021) |
| All-time low | $0.2138 (Jul 17, 2024) |
| 52-week high | $0.4387 |
| 52-week low | $0.2829 |
| Median price | $0.3515 |
| Average price | $0.3600 |
| Largest weekly change | +85.8% (Nov 22, 2023) |
| Weeks tracked | 300 |
| Tracking since | Jan 6, 2021 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 65% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Levonorgestrel and Ethinyl Estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEVONOR-ETH ESTRAD TRIPHASIC?
The current National Average Drug Acquisition Cost (NADAC) for LEVONOR-ETH ESTRAD TRIPHASIC, manufactured by Lupin Pharmaceuticals Inc., is $0.3236 per EA (NDC 68180085773), effective Sep 30, 2026.
How has the price of LEVONOR-ETH ESTRAD TRIPHASIC changed over time?
Over the history we have for it, the NADAC for LEVONOR-ETH ESTRAD TRIPHASIC has declined 31.0%. It has been tracked across 300 weekly CMS publications since Jan 6, 2021.
What are the highest and lowest recorded NADAC prices for LEVONOR-ETH ESTRAD TRIPHASIC?
Since Jan 6, 2021, the NADAC for LEVONOR-ETH ESTRAD TRIPHASIC has ranged from a low of $0.2138 (Jul 17, 2024) to a high of $0.5249 (Apr 14, 2021), with a median of $0.3515 per EA.
Are there cheaper alternatives to LEVONOR-ETH ESTRAD TRIPHASIC?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CHATEAL EQ-28 TABLET, is $0.1135 per EA — about 65% below LEVONOR-ETH ESTRAD TRIPHASIC.
Who manufactures LEVONOR-ETH ESTRAD TRIPHASIC?
LEVONOR-ETH ESTRAD TRIPHASIC (NDC 68180085773) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.